Cytosorbents (NASDAQ:CTSO) Posts Earnings Results, Misses Estimates By $0.02 EPS

Cytosorbents (NASDAQ:CTSO) released its quarterly earnings results on Wednesday. The medical research company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.02), Zacks reports. Cytosorbents had a negative return on equity of 191.30% and a negative net margin of 31.85%.The firm had revenue of $8.86 million for the quarter, compared to analysts’ expectations of $9.40 million.

Here are the key takeaways from Cytosorbents’ conference call:

• CytoSorbents reported Q1 2026 revenue of $8.9 million, up 2% year over year, with growth in direct international markets outside Germany offset by weakness in Germany and disruptions in the Middle East.
• International direct sales grew 13% year over year, which management said reflected better physician awareness, stronger execution, and improving adoption in key accounts.
• Gross margin was 69%, and the company said the slight decline was intentional because it slowed production to reduce inventory and improve working capital.
• The company said it now has clear FDA direction for DrugSorb-ATR, including a planned pre-submission for DOAC removal, though the new De Novo filing for ticagrelor removal may slip to late 2026 or early 2027 due to additional mechanistic data requests.
• Management highlighted growing clinical evidence for DrugSorb-ATR and CytoSorb, including STAR-T publication results showing the device was safe and reduced severe bleeding in CABG patients, plus upcoming presentations at major cardiovascular conferences.

Cytosorbents Stock Performance

CTSO traded down $0.03 during midday trading on Thursday, reaching $0.54. The company had a trading volume of 305,628 shares, compared to its average volume of 54,783. The company has a debt-to-equity ratio of 2.82, a quick ratio of 1.58 and a current ratio of 2.13. The stock has a market cap of $33.97 million, a PE ratio of -2.85 and a beta of 1.43. Cytosorbents has a 12-month low of $0.50 and a 12-month high of $1.39. The business has a 50-day moving average price of $0.64 and a two-hundred day moving average price of $0.68.

Analysts Set New Price Targets

Several research firms recently weighed in on CTSO. Weiss Ratings restated a “sell (e+)” rating on shares of Cytosorbents in a report on Wednesday, April 8th. D. Boral Capital restated a “buy” rating and set a $10.00 price target on shares of Cytosorbents in a report on Thursday, March 26th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $5.38.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC boosted its stake in Cytosorbents by 127.3% in the third quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock valued at $61,000 after acquiring an additional 36,790 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Cytosorbents by 149.2% in the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after acquiring an additional 37,519 shares during the last quarter. Vanguard Group Inc. boosted its stake in Cytosorbents by 3.7% in the third quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock valued at $2,059,000 after acquiring an additional 79,535 shares during the last quarter. Avenir Corp raised its position in shares of Cytosorbents by 2.9% in the fourth quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock valued at $3,343,000 after purchasing an additional 147,261 shares during the period. Finally, CIBC Bancorp USA Inc. bought a new stake in shares of Cytosorbents in the third quarter valued at approximately $161,000. 32.87% of the stock is currently owned by hedge funds and other institutional investors.

About Cytosorbents

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.